Last reviewed · How we verify
Hydrocortison
At a glance
| Generic name | Hydrocortison |
|---|---|
| Sponsor | Cairo University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Post-operative Corticosteroid Treatment After Mitral Valve Surgery (PHASE2, PHASE3)
- Therapy With Hydrocortisone, Ascorbic Acid, Thamine in Patients With Sepsis (NA)
- Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock
- Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock. (PHASE2, PHASE3)
- Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) (PHASE4)
- Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer (PHASE3)
- Effects of Hydrocortisone on Social Cognition and Memory (NA)
- Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrocortison CI brief — competitive landscape report
- Hydrocortison updates RSS · CI watch RSS
- Cairo University portfolio CI